JIANGSU GDK(SH:688670)2021-10-18 16:00Financial Performance - The company's operating revenue for Q3 2021 reached ¥316,767,790.30, representing an increase of 81.06% compared to the same period last year[5] - Net profit attributable to shareholders was ¥123,380,194.62, a year-on-year increase of 123.40%[5] - The net profit excluding non-recurring gains and losses was ¥120,485,663.84, up 120.16% from the previous year[5] - Basic and diluted earnings per share were both ¥1.53, reflecting an increase of 82.14% compared to the same period last year[6] - Total operating revenue for the first three quarters of 2021 reached ¥348,862,016.53, an increase from ¥262,359,887.82 in the same period of 2020, representing a growth of approximately 33%[24] - Net profit for the first three quarters of 2021 was ¥100,075,142.54, up from ¥48,419,117.67 in 2020, reflecting a growth of approximately 106.7%[25] - Basic and diluted earnings per share for the third quarter of 2021 were both ¥1.41, compared to ¥0.73 in the same quarter of 2020, marking an increase of 92.5%[25] Assets and Liabilities - Total assets increased by 123.47% to ¥1,738,571,446.61 compared to the end of the previous year[6] - Total assets as of the end of the third quarter of 2021 amounted to ¥1,738,571,446.61, significantly higher than ¥777,975,861.13 at the end of the same period in 2020[22] - Total liabilities for the third quarter of 2021 were ¥259,586,362.93, down from ¥535,471,481.99 in 2020, indicating a reduction of approximately 51.5%[21] - The company's total equity reached ¥1,478,985,083.68 by the end of the third quarter of 2021, compared to ¥242,504,379.14 in the same period of 2020, showing a substantial increase of about 509%[22] Cash Flow - The company reported a cash flow from operating activities of ¥25,239,042.68, a decrease of 25.63% compared to the previous year[6] - Operating cash inflow for the first three quarters of 2021 was CNY 339,639,556.36, a significant increase from CNY 168,733,413.73 in the same period of 2020, representing a growth of 101.0%[27] - Net cash flow from operating activities decreased to CNY 25,239,042.68 in 2021 from CNY 33,935,881.85 in 2020, a decline of 25.6%[27] - Total cash outflow from investment activities was CNY 848,163,575.38, compared to CNY 43,392,098.16 in the previous year, indicating a substantial increase in investment spending[28] - Net cash flow from financing activities rose to CNY 829,125,729.89 in 2021, up from CNY 16,638,747.35 in 2020, reflecting a significant increase in financing efforts[28] Research and Development - The company's R&D investment totaled ¥9,703,935.67, which is 3.06% of operating revenue, a decrease of 1.60 percentage points year-on-year[6] - Research and development expenses for the first three quarters of 2021 were ¥28,861,387.14, compared to ¥22,041,130.46 in 2020, reflecting an increase of approximately 31%[24] Shareholder and Stock Information - The company plans to grant 800,000 restricted stocks under the 2021 incentive plan, representing 0.91% of the total share capital[17] - The first grant of 652,000 restricted stocks was approved, accounting for 0.74% of the total share capital[18] - The company’s employee stock incentive plan involves 369 participants, representing 93.42% of the total employees[17] - The company’s major shareholders include China Industrial Bank and China Construction Bank, with significant holdings in various investment funds[15] Investment and Market Strategy - The increase in revenue was primarily driven by steady growth in the sales of quadrivalent influenza vaccines[10] - The company emphasized its focus on technological innovation and quality management, which contributed to improved gross margins and reduced sales expenses[10] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[24]